Abstract

H.B. Fuller will report fiscal third-quarter results on September 23, 2026 Post-Mkt; this preview summarizes last quarter’s performance, the company’s latest quarter guidance and consensus forecasts, and the prevailing institutional view on the stock ahead of the print.

Market Forecast

For the current fiscal quarter, forecasts indicate revenue of 0.95 billion US dollars, implying year-over-year growth of 5.84%, and adjusted EPS of 1.47, up 18.01% year over year; EBIT is projected at 139.22 million US dollars with expected year-over-year growth of 6.03%. Management’s execution focus centers on mix discipline and cost control, and no formal guidance for gross margin or net margin has been disclosed in the forecast dataset.

The core business emphasis remains on scaling earnings efficiency, with discipline on pricing and procurement tailwinds highlighted as drivers of margin resilience and operating leverage. Hygiene, Health and Consumables adhesives stands out as the most promising segment in the near term, having generated 421.86 million US dollars last quarter with healthy profitability signals and continued commercial momentum into the second half.

Last Quarter Review

In the prior quarter, H.B. Fuller delivered revenue of 0.95 billion US dollars, a gross profit margin of 33.78%, GAAP net profit attributable to shareholders of 67.81 million US dollars, a net profit margin of 7.14%, and adjusted EPS of 1.41, with revenue up 5.81% year over year and adjusted EPS up 19.49% year over year. Revenue exceeded internal estimates and adjusted EPS modestly outpaced expectations, while GAAP net profit grew sharply quarter over quarter by 222.19%, underscoring improved price-cost spread and operating discipline.

A key financial highlight was the combination of steady top-line execution and cost capture, which supported an expansion in profitability and a better-than-anticipated earnings conversion from revenue. In the business mix, Hygiene, Health and Consumables adhesives generated 421.86 million US dollars, Engineering Adhesives delivered 283.24 million US dollars, and Construction Products contributed 245.17 million US dollars.

Current Quarter Outlook

Main business drivers and earnings mechanics

The current quarter outlook is built on revenue of 0.95 billion US dollars and adjusted EPS of 1.47, implying mid-single-digit revenue growth and a strong double-digit percentage increase in per-share earnings. The operating playbook continues to emphasize pricing discipline, supply-chain cost capture, and a product-mix shift toward higher-value solutions, which together are supportive of sustained gross margin resilience. With EBIT guided to 139.22 million US dollars, up 6.03% year over year, the company’s profit algorithm suggests incremental operating leverage, as fixed cost absorption benefits continue while spending is prioritized toward growth programs with the clearest payback.

A pivotal watch item for the quarter is the price-cost spread: input costs have moderated in aggregate, and prior actions on procurement and formulations remain a tailwind, which can buttress margins even amid uneven shipment patterns across end-use categories. Execution in contract renewals and disciplined pricing pass-through remains relevant for protecting gross profit dollars, particularly in accounts where price concessions were selectively rolled back earlier in the year to secure volume commitments. In parallel, operational cadence in cash conversion is expected to remain a focus, with working capital efficiency efforts aiding free cash flow seasonality as the company progresses through the back half of the fiscal year.

Foreign exchange is an important swing factor for reported results given the company’s global footprint; an adverse FX translation would affect top-line comparability but is manageable at the earnings line if mix and cost offsets hold. From an expense standpoint, labor and logistics are being actively managed, and project timing on productivity initiatives could contribute marginally to opex efficiency within the quarter. Taken together, the framework implies that even if volume is mixed by end-market, pricing, cost execution and mix should allow adjusted EPS to track the forecast trajectory.

Most promising business and near-term growth catalysts

Hygiene, Health and Consumables adhesives, at 421.86 million US dollars last quarter, remains the most visible engine for earnings durability into this print. The segment benefits from resilient demand patterns and the commercial discipline that supports stable or improving margins. Price realization actions earlier this year were designed to align with customer value delivery and raw material trends; as such, this segment is positioned for relatively favorable incremental margins in the near term, assuming no disruptive feedstock volatility.

Beyond the current quarter, ongoing portfolio upgrades and product enhancements in premium hygiene and health applications continue to create a foundation for sustained growth. Additionally, the planned acquisition of Advanced Medical Solutions Group introduces a pipeline of medical-grade adhesive platforms and devices that can expand the addressable opportunity and enrich the margin mix once closed. While the acquisition is not yet reflected in the quarter under review and closing is contingent on meeting remaining conditions, investor interest in potential medical adjacency benefits has been rising; integration timing and synergy phasing will be important to monitor once the transaction completes.

Medical-adjacent adhesives often carry attractive economics, and the broadening of product architecture into surgical and wound-care use cases can enable deeper customer integration and multi-year program wins. Commercially, the firm’s ability to cross-sell into existing channels and leverage established operations would be a differentiator in ramping these offerings efficiently. In the near term, the principal takeaway is that the hygiene and medical-oriented portfolio has a clear line of sight to demand resilience and margin support, making it the segment with the most visible growth and profitability traction this quarter.

Stock price swing factors for this quarter

Short-term share performance will be influenced by three themes: operational delivery versus guidance, portfolio actions, and capital structure planning. On operations, the street is looking for confirmation that revenue can land near 0.95 billion US dollars with supportive margins, which would validate the thesis that pricing discipline and cost management continue to offset pockets of volume variability. A beat on adjusted EPS relative to the 1.47 marker would likely hinge on gross profit execution and opex control, as well as any incremental benefits from productivity and procurement programs.

Portfolio moves remain a major narrative driver. There is active external interest in the Construction Products (Building Adhesive Solutions) division, reflected in recent unsolicited cash proposals to acquire the unit. The board has indicated that recent offers undervalued the segment and did not account for its future earnings contribution, and it has declined to proceed on the proposals. The market is therefore monitoring whether any further strategic alternatives are entertained, whether additional parties surface, or whether the focus remains squarely on organic performance and medical-growth expansion via the AMS transaction. Any change in stance could re-rate the stock by altering growth and margin mix, while steady-as-is guidance will likely keep attention on execution and de-leveraging.

Leverage and financing costs form the third swing factor. The company has communicated an accelerated de-leveraging plan to maintain balance-sheet flexibility as it navigates the planned acquisition and ongoing investments. Interest expense sensitivity is a consideration this quarter, but the earnings power implied by the 6.03% year-over-year EBIT growth forecast suggests capacity to absorb financing costs provided operational momentum continues. Free cash flow cadence will also be watched for signs of discipline, particularly around inventory turns and receivables, which can act as a secondary support for de-leveraging.

Event risk also intersects with valuation this quarter. Any incremental updates to the AMS deal timeline, synergy targets, or integration phasing could shift sentiment and the applied trading multiple, as could new developments around activist engagement regarding the portfolio. On balance, the clearer the line from operating drivers to sustained EPS delivery, the more supportive the near-term stock reaction should be, especially if guidance commentary reaffirms the path to expanding adjusted profitability into year-end.

Analyst Opinions

Among the views gathered, the majority are constructive on H.B. Fuller’s near-term earnings trajectory. In terms of ratio, the collated opinions skew bullish versus bearish, with the dominant cohort expecting the company to at least meet, and potentially exceed, the mid-single-digit revenue growth and double-digit adjusted EPS expansion implied by current forecasts.

JPMorgan upgraded H.B. Fuller to Overweight and highlighted improved confidence in the company’s price-cost framework and operating execution through the back half of the fiscal year. The upgrade underscores a view that the earnings algorithm can continue to compound through disciplined pricing, procurement savings, and selective growth investments, with valuation supported by a clearer path to adjusted EPS expansion. UBS maintained a neutral rating but characterized the second-half outlook as conservative and beatable, framing pricing realization as a swing factor; in practice, that aligns with a mildly positive stance on quarterly performance even if the top-down rating label remains neutral.

The majority opinion coalesces around several core assertions relevant to the upcoming print. First, adjusted EPS of around 1.47 is seen as attainable given the combination of price discipline, modest cost tailwinds, and mix benefits. Second, while revenue growth of 5.84% year over year sits in the mid-single-digit range, a relatively high-quality gross profit mix reduces the reliance on outsized volume growth to meet earnings expectations. Third, the possibility of incremental upside is linked to better-than-anticipated cost capture or a favorable shift in product mix, which could lift margins without requiring materially higher volume.

Institutional commentary also emphasizes that execution on cash conversion and controlled operating expenses can provide an additional buffer to consensus. Some institutions view the portfolio narrative—particularly the AMS acquisition and the rejected bids for Construction Products—as a valuation headwind if uncertainty lingers, but not a near-term impediment to hitting quarterly numbers. Rather, they see the quarter as a referendum on operational consistency and an opportunity for management to reaffirm its path to sustained adjusted EPS growth while addressing capital allocation priorities.

Overall, the prevailing institutional stance tilts positive for the quarter: the forecasted revenue base of 0.95 billion US dollars and adjusted EPS of 1.47 are considered appropriately calibrated, and the balance of risks is seen as manageable under current pricing, cost, and mix assumptions. A focus on reiterating the operating framework, clarifying near-term portfolio intentions, and updating de-leveraging milestones could further align expectations and support the constructive bias reflected in the majority view. Should reported results validate the current forecast trajectory and management reiterate confidence in the earnings path, analysts expect valuation to remain anchored to a narrative of steady adjusted profit expansion into the fiscal year’s close.